Published in J Neurol Neurosurg Psychiatry on December 01, 1988
Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis (1981) 3.07
Overwhelming strongyloidiasis: an unappreciated opportunistic infection. Medicine (Baltimore) (1978) 2.98
Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults. Am J Med (1981) 2.36
Fatal strongyloidiasis in patients receiving corticosteroids. N Engl J Med (1966) 2.12
Gram-negative bacillary meningitis. Am J Med (1975) 1.64
Steroid therapy and strongyloidiasis. Lancet (1966) 1.44
A FATAL CASE OF STRONGYLOIDIASIS. J Pathol Bacteriol (1964) 1.34
Disseminated strongyloidiasis with cerebral involvement. A complication of corticosteroid therapy. Am J Med (1973) 1.30
Meningitis caused by gram-negative bacilli. Ann Intern Med (1980) 1.27
Strongyloides stercoralis hyperinfection syndrome: how often is it missed? Q J Med (1987) 1.14
Strongyloides stercoralis hyperinfestation syndrome with Escherichia coli meningitis: report of two cases. J Clin Pathol (1986) 1.11
Brain abscess caused by Strongyloides stercoralis. Arch Neurol (1982) 0.97
A fatal case of strongyloidiasis with Strongyloides larvae in the meninges. Trans R Soc Trop Med Hyg (1976) 0.97
Fatal strongyloidiasis in Hodgkin's disease after immunosuppressive therapy. J Trop Med Hyg (1970) 0.95
Strongyloidiasis with massive hyperinfection. N Y State J Med (1975) 0.94
Disseminated Strongyloides stercoralis in an immunosuppressed host. Mayo Clin Proc (1978) 0.92
Case report: Antemortem diagnosis of central nervous system strongyloidiasis. Am J Med Sci (1979) 0.83
Strongyloides infection and meningitis in an immunocompromised host. Am J Trop Med Hyg (1982) 0.83
Strongyloidiasis. J Pediatr (1959) 0.81
Fatal strongyloidiasis in a patient receiving corticosteroids. Indian J Pathol Bacteriol (1974) 0.81
Strongyloides stercoralis: immunobiological considerations on an unusual worm. Parasitol Today (1986) 0.80
ESCHERICHIA COLI MENINGITIS IN ADULTS. Arch Neurol (1965) 0.78
Escherichia coli meningitis in adults: neurosurgical and neuropathological considerations. J Neurosurg (1968) 0.78
Disseminated strongyloidiasis: detectable and preventable. JAMA (1980) 0.77
Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci (2003) 10.44
Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell (1997) 6.55
Survey of use of anticoagulation in patients with atrial fibrillation. BMJ (1993) 5.71
Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology (2003) 3.75
Neural correlates of motor recovery after stroke: a longitudinal fMRI study. Brain (2003) 3.65
The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology (2001) 3.04
Neural correlates of outcome after stroke: a cross-sectional fMRI study. Brain (2003) 3.04
Microscopic air embolism during cerebral angiography and strategies for its avoidance. Lancet (1993) 2.84
Homologous ribosomal protein genes on the human X and Y chromosomes: escape from X inactivation and possible implications for Turner syndrome. Cell (1990) 2.70
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology (1999) 2.54
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54
Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain (1990) 2.53
Utility values and age-related macular degeneration. Arch Ophthalmol (2000) 2.48
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. J Neurol Neurosurg Psychiatry (2000) 2.44
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology (2009) 2.14
Percutaneous transluminal angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst Rev (2007) 2.10
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
The Functional Independence Measure: a comparative validity and reliability study. Disabil Rehabil (1995) 2.04
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
Fatal cerebral reperfusion hemorrhage after carotid stenting. Stroke (1999) 2.01
Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry (2000) 2.01
Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain (2002) 2.01
Immunologic studies in IgA nephropathy. Kidney Int (1980) 1.99
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain (1998) 1.99
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry (2005) 1.97
Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology (1993) 1.87
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Angiotensin-converting enzyme gene deletion polymorphism. A new risk factor for lacunar stroke but not carotid atheroma. Stroke (1995) 1.77
Digital subtraction angiography (DSA) of the extracranial cerebral vessels: a direct comparison between intravenous and intra-arterial DSA. Clin Radiol (1991) 1.74
The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol (1997) 1.73
Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain (1996) 1.69
Community services in multiple sclerosis: still a matter of chance. J Neurol Neurosurg Psychiatry (2000) 1.68
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68
Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67
Evidence-based measurement: which disability scale for neurologic rehabilitation? Neurology (2001) 1.66
Evidence for a genetically stable strain of Campylobacter jejuni. Appl Environ Microbiol (2001) 1.65
Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based, case-control study. J Neurol Neurosurg Psychiatry (2010) 1.65
Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry (2002) 1.64
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology (2008) 1.62
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology (1997) 1.60
Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry (2005) 1.59
The experimental neuropathy in rats caused by p-bromophenylacetylurea. J Neurol Neurosurg Psychiatry (1968) 1.59
Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology (2001) 1.58
Cerebellar ectopia presenting in adult life. Br Med J (1969) 1.58
Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology (1999) 1.58
Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology (2001) 1.58
Quality of life with macular degeneration: perceptions of patients, clinicians, and community members. Br J Ophthalmol (2003) 1.57
Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology (2010) 1.56
Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. Brain (2007) 1.55
Control of abscisic acid synthesis. J Exp Bot (2000) 1.55
Measuring change in disability after inpatient rehabilitation: comparison of the responsiveness of the Barthel index and the Functional Independence Measure. J Neurol Neurosurg Psychiatry (1999) 1.54
Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry (1999) 1.53
Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in amyotrophic lateral sclerosis. Brain (2006) 1.53
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Should we screen for familial intracranial aneurysm? Stroke (1999) 1.53
A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain (1994) 1.53
Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain (1995) 1.53
Diffusion tractography based group mapping of major white-matter pathways in the human brain. Neuroimage (2003) 1.51
Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol (2000) 1.51
Altered middle lamella homogalacturonan and disrupted deposition of (1-->5)-alpha-L-arabinan in the pericarp of Cnr, a ripening mutant of tomato. Plant Physiol (2001) 1.50
From diffusion tractography to quantitative white matter tract measures: a reproducibility study. Neuroimage (2003) 1.49
Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome. Health Technol Assess (2004) 1.49
IgA nephropathy: a syndrome of uniform morphology, diverse clinical features and uncertain prognosis. Clin Nephrol (1977) 1.49
The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology (2009) 1.49
Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology (1990) 1.47
Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications (2000) 1.46
Small deep cerebral infarcts associated with occlusive internal carotid artery disease. A hemodynamic phenomenon? Arch Neurol (1990) 1.46
Cotton-wool spots. Retina (1986) 1.45
Detection of asymptomatic cerebral embolic signals with Doppler ultrasound. Lancet (1994) 1.45
Painful extremities and neurological disorder in essential thrombocythaemia. J R Soc Med (1984) 1.44
A single consultation cerebrovascular disease clinic is cost effective in the management of transient ischaemic attack and minor stroke. J R Coll Physicians Lond (2001) 1.43
The value of serological testing for Lyme disease in the UK. Br J Rheumatol (1995) 1.43
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci (1994) 1.43
The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain (2000) 1.41
Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol (2003) 1.41
Towards a european network for multiple sclerosis trials (ENMST). Mult Scler (2003) 1.40
Validation and characterization of the L5178Y/TK+/- mouse lymphoma mutagen assay system. Mutat Res (1979) 1.39
Ultrasonic detection of cerebral emboli in carotid stenosis. Lancet (1993) 1.38
Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol (1994) 1.35
Genetic predisposition to melanoma and other skin cancers in Australians. Med J Aust (1971) 1.35
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology (2004) 1.34
The correlation of coronary angiography and the electrocardiographic response to maximal treadmill testing in 76 asymptomatic men. Circulation (1973) 1.34
A clinical and laboratory study of benign multiple sclerosis. Q J Med (1986) 1.31
Central motor conduction in multiple sclerosis: evaluation of abnormalities revealed by transcutaneous magnetic stimulation of the brain. J Neurol Neurosurg Psychiatry (1988) 1.31
Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain (2002) 1.30
EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry (1992) 1.29
The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain (2001) 1.29
Spinal cord atrophy and disability in MS: a longitudinal study. Neurology (1998) 1.28
Evaluating neurological outcome measures: the bare essentials. J Neurol Neurosurg Psychiatry (1996) 1.28
Fundamental importance of arterial oxygen content in the regulation of cerebral blood flow in man. Brain (1985) 1.28
Abnormalities of cerebral perfusion in multiple sclerosis. J Neurol Neurosurg Psychiatry (2004) 1.27
Aging of the adult human brain: in vivo quantitation of metabolite content with proton magnetic resonance spectroscopy. J Magn Reson Imaging (1999) 1.27
Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology (1996) 1.25